HLA-B15 Peptide Ligands Are Preferentially Anchored at Their C Termini

Kiley R. Prilliman, Kenneth W. Jackson, Mark Lindsey, Jihua Wang, David Crawford and William H. Hildebrand

The Journal of Immunology

References　This article **cites 42 articles**, 20 of which you can access for free at:
http://www.jimmunol.org/content/162/12/7277.full#ref-list-1

Why *The JI*? Submit online.

- **Rapid Reviews! 30 days*** from submission to initial decision

- **No Triage!** Every submission reviewed by practicing scientists

- **Fast Publication!** 4 weeks from acceptance to publication

*average

Subscription　Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions　Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts　Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts

HLA-B15 Peptide Ligands Are Preferentially Anchored at Their C Termini[1]

Kiley R. Prilliman,* Kenneth W. Jackson,[†] Mark Lindsey,* Jihua Wang,[†] David Crawford,* and William H. Hildebrand[2]*

Therapies to elicit protective CTL require the selection of pathogen- and tumor-derived peptide ligands for presentation by MHC class I molecules. Edman sequencing of class I peptide pools generates "motifs" that indicate that nonameric ligands bearing conserved position 2 (P2) and P9 anchors provide the optimal search parameters for selecting immunogenic epitopes. To determine how well a motif represents its individual constituents, we used a hollow-fiber peptide production scheme followed by the mapping of endogenously processed class I peptide ligands through reverse-phase HPLC and mass spectrometry. Systematically mapping and characterizing ligands from B*1508, B*1501, B*1503, and B*1510 demonstrate that the peptides bound by these B15 allotypes i) vary in length from 7 to 12 residues, and ii) are more conserved at their C termini than their N-proximal P2 anchors. Comparative peptide mapping of these B15 allotypes further pinpoints endogenously processed ligands that bind to the allotypes B*1508, B*1501, and B*1503, but not B*1510. Overlapping peptide ligands are successful in binding to B*1501, B*1503, and B*1508 because these B15 allotypes share identical C-terminal anchoring pockets whereas B*1510 is divergent in the C-terminal pocket. Therefore, endogenous peptide loading into the B15 allotypes requires that a conserved C terminus be anchored in the appropriate specificity pocket while N-proximal anchors are more flexible in their location and sequence. Queries for overlapping and allele-specific peptide ligands may thus be contingent on a conserved C-terminal anchor.   *The Journal of Immunology,* 1999, 162: 7277–7284.

The polymorphic heavy chains of class I molecules are encoded within the MHC and, upon assembling into heterodimers with β_2-microglobulin (β_2m),[3] are responsible for selectively gathering endogenously processed peptides (1, 2). Once peptides are collected, mature class I molecules bring their peptide cargo to the cell surface where receptors on CD8[+] T lymphocytes engage the class I molecules to inspect the ligands (3). CTL may then be triggered by class I molecules bearing virus- or tumor-derived peptides (4–7), while peptides characteristic of healthy cells typically provoke no T cell response.

Lymphocytes of the T lineage are restricted to seeing peptide Ags strictly in the context of MHC molecules (8). Therefore, triggering a cytotoxic T cell response requires that an Ag first be broken into peptide fragments, intracellularly bound by class I MHC molecules, and subsequently presented to T lymphocytes at the cell surface (9). Because CTL play a critical role in eliminating both infected and neoplastic cells, intensive research efforts have

been directed toward stimulating T cells capable of eliminating viruses and tumors (10–16). To elicit a protective CTL response, one must determine which of the class I-presented peptide epitopes are unique to naturally infected or transformed cells. Once the class I epitopes that distinguish diseased cells are identified, they can be therapeutically applied to elicit protective CTL targeted to these specific epitopes.

The search for epitopes unique to infected/neoplastic cells typically proceeds via generalized, often indirect methods. For example, to begin one typically Edman sequences a pool of class I-eluted ligands containing thousands of individual peptides. The resulting sequence produces a pooled "motif" that summarizes the population of individual peptide epitopes with a consensus amino acid sequence and length (17). Such pooled sequence data can then be used to query a pathogen or tumor-specific protein sequence, from which putative class I-presented vaccine epitopes coincident with given motifs can be selected (12, 18, 19). Motifs derived from pooled sequencing of human class I-eluted peptides are invariably 9 aa in length. The overwhelming majority of these peptide motifs also define dominant or strong "anchors" at position 2 (P2) and P9 (20). One interpretation of this motif data is that endogenous peptide loading requires a nonamer with particular P2 and P9 anchors. Indeed, most searches for putative viral or tumor class I-presented epitopes are predicated upon nonameric templates with appropriate P2 and P9 anchors.

The fractionation of peptides before Edman analysis in a previous report resulted in amino acid sequence data demonstrating that the components of a peptide pool can vary considerably from the overall motif (21). Several studies characterizing individual immunogenic epitopes have also demonstrated that CTL recognize peptide ligands inconsistent with the length or P2/P9 anchors indicated by pooled motifs (22, 23). Because a motif is actually a composite representing thousands of individual constituents, it is not surprising that a fraction of these constituents do not match the

Table I. *Ag binding groove-localized amino acid substitutions that distinguish the B*1508, B*1501, B*1503, and B*1510 allotypes*

	Residue Position[a]						
	24	45	46	63	67	116	156
consensus	A	M	A	E	S	S	W
B*1508	–	–	–	N	F	–	–
B*1501	–	–	–	–	–	–	–
B*1503	S	E	E	–	–	–	L
B*1510	S	E	E	N	C	Y	L

[a] Residues are numbered from the N terminus of the mature class I heavy chains. Positions of identity with the consensus (italics) drawn from B*1501 are indicated by dashes (–).

composite. However, the extent of deviation around composite motifs remains unrealized, and with accumulating data demonstrating that class I peptide ligands need not fit predicted pooled motifs, the search parameters for identifying putative class I ligands become ambiguous.

An ongoing effort in our laboratory is the systematic characterization of endogenously processed class I peptide ligands. Our approach is to map multiple ligands from divergent class I molecules, after which we directly compare the peptide maps (24). The overall goal of comparatively analyzing peptides from different MHC molecules is to prescribe the rules that allow or prohibit natural peptide binding across class I Ag binding groove polymorphisms. We have sequenced >200 endogenously processed peptides from a series of four HLA-B15 alleles that differ sequentially in their Ag binding grooves. Analysis of these HLA-B15 ligands depicts the range of functional variability around a peptide motif and demonstrates the key role played by a ligand's C terminus during endogenous peptide loading.

Materials and Methods

Transfectants, cell culture, and purification of soluble HLA (sHLA)

Transfectants were established and cultured as previously described with some modifications (24). Briefly, the cloned coding regions of the four alleles B*1501, B*1503, B*1508, and B*1510, which differ by up to 7 aa within their Ag binding grooves (Table I), were truncated by RT-PCR using primers 5PXI (5′-GGGCTCTAGAGGACTCAGAATCTCCCCA GACGCCGAG-3′) and 3PEI (5′-CCGCGAATTC*TCA*TCTCAGGGT GAG-3′). This yielded products that terminated at codon 300 (inserted stop shown in bold italic) and were flanked by 5′ *Xba*I and 3′ *Eco*RI restriction sites (underlined). The products were subcloned into the pcDNA3.1(−) expression vector (Invitrogen, Carlsbad, CA), verified by DNA sequencing, and electroporated into the class I-negative cell line 721.221 (25), which was then selected with 1.5 mg/ml G418 (Mediatech, Herndon, VA). Transfectants were screened by ELISA using W6/32 (26) as the primary Ab and an anti-β_2m HRP-conjugated secondary Ab (Dako, Carpinteria, CA), and positive wells were subcloned by limiting dilution. sHLA-producing clones were then expanded and cultured for 4–6 wk in a Cell Pharm 3000 (Unisyn Technologies, San Diego, CA) hollow-fiber bioreactor system following inoculation of 4×10^9 viable cells. Basal media was unsupplemented RPMI 1640 with 2 mM L-glutamine (Mediatech), while the extracapillary space (ECS) feed consisted of RPMI 1640 with L-glutamine and 10% FCS. Harvests collected from the ECS throughout this time span averaged 18 L at 6–8 mg/L sHLA; they were centrifuged to remove cell debris and then passed at 5 ml/min over a 100-ml bed volume column of W6/32 coupled to cyanogen bromide-activated Sepharose 4B (Amersham Pharmacia Biotech, Piscataway, NJ) using the GradiFrac System (Amersham Pharmacia Biotech); separate matrices were prepared and used for each sHLA type. After washing the column with 1–2 L of 20 mM sodium phosphate buffer, complexes were eluted with 200 ml of 0.2 N acetic acid, pH 2.7, at 6.5 ml/min with 4.5 ml fractions automatically collected.

Isolation, reverse-phase HPLC (RP-HPLC) separation, and Edman sequencing of peptides

Peptides were extracted from eluted sHLA by pooling the fractions of UV absorbance at 280 nm (A_{280}), adding glacial acetic acid to 10%, and heating for 10 min at 70°C. Upon cooling, peptides were separated from heavy chains, β_2m, and BSA through a stirred cell with a 3-kDa YM membrane (Amicon, Beverly, MA). Isolated peptides were purified of salts and free amino acids by a steep RP-HPLC gradient of 0–100% acetonitrile with trifluoroacetic acid (TFA) (0.06%) in 1 min, held at 100% for 10 min before return to 0% in 1 min on a 2.1 × 100 mm C18 column (Vydac, Hesperia, CA), during which the region corresponding to A_{214} was manually collected. While 1/100th of this was used for pooled Edman sequencing, aliquots approximating 400 μg of extracted peptides as based upon ELISA estimates of 2% (24) and an assumed handling loss of up to 50% (27) were next injected in a volume of 100 μl of 10% acetic acid and separated by RP-HPLC on a 2.1 × 150 mm C18 column (Michrom Biosources, Auburn, CA) using a gradient of 2–10% acetonitrile with 0.06% TFA in 0.02 min and 10–60% of the same buffer in 60 min at 180 μl/min with fractions collected automatically every minute. The dye methyl violet base B (Aldrich, Milwaukee, WI) was added in a quantity of 500 ng to the 100-μl injection aliquots before this final RP-HPLC separation to control for gradient consistency between runs. Of the resulting fractions, 1/9th of each was removed and stored at −20°C for later Edman sequencing as desired; the remaining 160 μl of each was concentrated by speed-vac to remove TFA and resuspended in 25 μl of 0.1% acetic acid in 50% methanol for nanoelectrospray mass spectrometry (NanoES-MS). Edman degradation, which was performed on peptide pools to obtain motifs and on fractions accordingly (21), was conducted for 14 cycles on a 492A pulsed liquid phase protein sequencer (Perkin-Elmer Applied Biosystems Division, Norwalk, CT) without cysteine derivatization, and raw data analysis was performed as previously described (28).

NanoES-MS ion map generation, comparison, and nanoelectrospray tandem mass spectrometry (NanoES-MS/MS) of potential ligand matches

To generate ion maps, 1–2 μl from each RP-HPLC was loaded into a gold/palladium alloy-coated borosilicate glass NanoES capillary tip (Protana, Odense, Denmark) by gentle centrifugation and subjected to NanoES-MS on an API III triple quadrupole mass spectrometer (PE SCIEX, Foster City, CA) equipped with a collision cell upgrade (29) and a NanoES ionization source inlet (Protana). Approximately 20–30 scans were collected with the following instrument settings: polarity, positive; needle voltage, 1000 V; orifice voltage, 65 V; N_2 curtain gas, 0.6 ml/min; step size, 0.2 atomic mass unit (amu); dwell time, 1.5 ms; and mass range, 325-1400 *m/z*. Spectra generated from the total ion chromatograms of each fraction were then compared with one another following baseline subtraction (spectral window width, 32 amu) and Kalman smoothing (Kalman gain, 2). Ion matches between spectra were located through data centroiding (minimum distance, 0.3 amu; minimum width, 0.5 amu) and/or direct visual assessment, the latter proving beneficial in confirming matches of comparative intensity extremes. The states of identified matches were then evaluated by collisional dissociation of candidate ions via NanoES-MS/MS. Typical NanoES-MS/MS runs involved gating for an ion with the first quadrupole and scanning a range with the third quadrupole of 30–1000 *m/z* using a step size of 0.3 amu and a dwell time of 2 ms with lysine underivatized; the collision gas (Ar) was adjusted in each case to optimize fragmentation for the ion examined. NanoES-MS/MS data was evaluated and interpreted using the Predict Sequence algorithm (BioMultiView software, PE SCIEX) as well as PeptideSearch 3.0.2 (30) in instances of low ligand ionization/concentration or poor fragmentation. Advanced BLAST searches (31) were performed against databases available through the National Center for Biotechnology Information (National Institutes of Health, Bethesda, MD) web server to identify homology with currently catalogued sequences.

Results and Discussion

More than 200 individual ligands extracted from the four distinct HLA-B15 allotypes B*1508, B*1501, B*1503, and B*1510 were characterized in this study. Among our goals in examining these ligands was to test the hypothesis that endogenous peptides will overlap across polymorphisms in the Ag binding groove. Support

FIGURE 1. Strategy for comparative NanoES-MS ion mapping and NanoES-MS/MS analysis of HLA-B15 ligands. NanoES-MS spectral ion maps obtained individually from RP-HPLC fraction 8 for each of the four B15 allotypes were aligned for comparison (*a*). An expanded view of the range 495–555 *m/z*, or amu, is shown. The ion mass centered at 517.2 *m/z* (bold italics) matches across the spectra of B*1501, 1503, and 1508 (*top three panels*) but not B*1510 (*bottom panel*). This ion was subsequently selected for NanoES-MS/MS from fraction 8 of B*1501, B*1503, and B*1508. The homologous spectra resulting from fragmentation of the doubly charged ion $[M + 2H^+]^{2+}$ (*b*) classified the peptide as a positive match, or ligand overlap, across the three allotypes and allowed primary sequence derivation (*c*). N- and C-terminal peptide fragments present in all three NanoES-MS/MS spectra are labeled according to standard nomenclature (39, 40) in the *top panel* of *b* and underlined in *c*; immonium ions are indicated by their single-letter amino acid codes in *b*, and the sequences of internal cleavage products are also specified.

for this hypothesis comes primarily from in vitro peptide binding and/or competition assays (32–35), though a handful of endogenously loaded peptide overlaps have also been observed (28, 36–38). The ligands characterized here were those ion masses found in multiple B15 allotypes as demonstrated for one ion in Fig. 1*a*. Selected ions were then dissociated by NanoES-MS/MS, and the resulting fragment information was compared and interpreted (Fig. 1, *b* and *c*) to determine whether the ligands were sequence-identical matches.

Length and sequence variability exist among divergent B15 ligands

Individual peptide ligands characterized from the four B15 allotypes are shown in Fig. 2. The number of ligands for which either complete or partial sequences were obtained here was as follows: B*1508, *n* = 80; B*1501, *n* = 101; B*1503, *n* = 36; and B*1510, *n* = 35. The pooled motifs of peptides extracted respectively from B*1508, B*1501, B*1503, and B*1510 describe nonamers with various P2 and P9 dominant anchors and P3 auxiliary anchor preferences (Fig. 2), while individual ligand sequences range from 7 to

12 aa in length and demonstrate greater sequence heterogeneity at P2 than at their C-terminal anchors (Figs. 2 and 3). For allotypes B*1508, B*1501, and B*1503, a dominant C terminus was especially prominent, while B*1510 exhibited a P2 anchor nearly as strong as its C-terminal anchor (Fig. 3*b*). The C-terminal anchor was thus dominant among ligands bound by all four of the B15 allotypes characterized here.

In terms of length heterogeneity, the endogenous peptides eluted from B*1508, B*1501, B*1503, and B*1510 varied in length from 7 to 12 aa. A length breakdown of the peptides demonstrates that 7% are heptamers, 20% are octamers, 50% are nonamers, 20% are decamers, 2% are undecamers, and 1% are dodecamers. Further emerging from the length characterization of individual ligands is the observation that peptides bound by each of the B15 molecules respectively spanned ranges of 4 to 6 aa in length. For example, peptides eluted from B*1501 and B*1508 were 7–11 aa in length, those from B*1510 were 7–10 aa in length, and those from B*1503 were 7–12 aa in length (Fig. 3*a*). Coupling this length variability with P2 and C-terminal sequence flexibility leaves ~29% of the endogenously loaded peptides characterized in Fig. 2 as "ideal"

```
            B*1508                      B*1501                           B*1503                         B*1510

            1 2 3 4 5 6 7 8 9           1 2 3 4 5 6 7 8 9                 1 2 3 4 5 6 7 8 9               1 2 3 4 5 6 7 8 9

dominant    - P N - - - - - Y   dominant - Q K - - - - - Y      dominant - Q F P - - - - Y    dominant  - H Y P - - - - L
              A                            F                               K Y                            A
              F                            N                               R                              I
              K                            R                               V                              K
              R                            Y                               I                              S
              H                                                            N                              F
              Y                                                            A                              L
              I                                                                                           V
                                                                                                         T
strong      - - - E H R - - F   strong   - M P P G - - - F      strong   - M H G - R - - F
              D                            L H D I                         L E   V
              G                            V A G                           P D
              S                            E                                           strong  - - G R R I M - F
                                                                                                     D D V   L
                                                                                                     E K
                                                                                                     M E
                                                                                                     N
```

```
--WDRHTXF    AQYAAGESFY   ILGPPGSVY     --WDRHTXF    FLZAMGSTY    YMVT---F        AQFASGAGZ       SVSXPHAP
-----YT      TPHTZHDEY    XLGDVNMY      -----YT      GQYVVZPTY    APAV---VGY      -G--CDY         APFTGGNGX
XAZYEHTY     YM---FMY     AP---XVSY     ALGA--RGY    PMFDPPZTF    ------TGF       -----ZSF        EHVASSPAL
NGXAMHWTY    MVGXXPAT     YMSGXYGTF     XS---VEY     XAVGHSGGTY   PVPNVRXNY       NQZHGSAEY       HHAPCGVSX
VPCGZZSY     DPHYVSGHZF   ---AVVAZSY    AQFASGAGZ    -----PTY     -----TXSX       APMARGZY        NHAIVSTSV
TAZXHRGY     VVACV---Y    MPAGYNNVY     -G--CDY      -----PSY     YMVCNAEEY       ACGGCGZDY       GHZNSVTSV
NQZHGSAEY    PLA-N-HTY    XPVVPAAZTY    ---ZARGY     EPAMVXZCF    -----XRDXY      GQZZAVDF        SHZAPCTSV
TG----AY     VVAPITTGY    YMIDPSGVSY    ALNGRVTMY    VQGPVGVZY    ALGSZAXMPF      TPXGEPYZSY      FVARFVSX
-P--GZDEV    XAXYRRMY                   DPHAPPZY     VQXYYGSVV    VGYVDDTQF        ------GFY       HHSDGSVSL
NGYDGPNAGY   PLAMZXYTY                  XAZVZMTAY    GQPGAFXGGZY  DVEGWMSZY       AZVNSG-Y        MCZ-GMPAX
TPXGEPYZSY   -P-MPGXAY                  NQZHGSAEY    GPPHNGXRAY   AQHPSAXRF       AASSZV--PPZY    GHGANNDPAX
FVSNHAY      --TZSNAY                   FGXACXATSY   AAHWHVEAY    -----ZAY        NPPAZZPN        XHSZPAGPAX
SQFGGGSQY    MAAMVGVAVY                 APMARGZY     TPPTRRESY    GLGZTSAEF       -Q-DPPPDMZY     XHVVS--VX
SQFDHVTY     LPHQPLATY                  TG----AY     FPTDRRSZF    NAXG--RESSF     CPLSCFT         YHGSZNPEX
XAN--VT      FVTXNXEEY                  GQZZAVDF     YTGVSYXHF    TARVXSVEY       ASGFNGSZY       --------M
VDX---Y      GPZVMZHGY                  TPXGEPYZSY   AQASAPDAY    AAFCG---XV      IKADHVSTY       EHGXENGH
CPLSCFT      FQARXTEY                   GQHASVXSY    GQRKGAGSVF   XLH--ET         GP---PZY        AHZAPPPTX
FLZAMZSTY    AAAXV---VTY                FVSNHAY      VQYYXPF      ILGPPGSVY       DPD--GGSF       FTACZNPAX
TVXDSZTHY    XPEMGZFSY                  --------SY   ATGTAZNXNZY  XLGDVNMY        SQFGGGSQY       SHAGAGXVX
DPSGTZSGF    YV--VR-VF                  NPPAZZPN     VVACV---Y    VMGXTNANF       -Z--HTAY        GHXEGPXX
-----PGFY    AAPVGAXESY                 -Q-DPPPDMZY  VVAPITTGY    AVVTXZSDF       GZPPHNGFY       XHGGDHVX
-A-PHPMGY    YVA----PAF                 XQ--AGGZY    XQYTVGYF     AMNPTNTVF       XZADHVXPY       YHHDXVX
AQTVGYGEY    VGY--AHPGF                 SQFGGGSQY    PLFGZTAGZY   -VFVSHTTF       ----PGZVY       MAGAWCRX
------SVY    ------STY                  SQFDHVTY     A----ZXEY    XQGHHEMFY       GQRKGAGSVF      FH--XXX
TGNCSGTGTY   SPTYTHAVAF                 --AAHVPPGY   VAGGW---F    PQGZMA--Y       SZRXATXTY       EH---TVX
AQVNPSXTY    MPA--MVMAF                 FMDVGAPTVY   SGAXDRAYZF   HLTGNEATSF      AVGEQ--VY       MAX----VV
TP--ARAPT    XA---SYTY                  XAN--VT      VQGPVGTDF    YMIDPSGVSY      AZF---ZXY       ------PVX
SPGAETRAXY   VGYVDDTQF                  AQM--SEY     FQARXTEY                     AHAVZRVVY       XHYDRNZX
YX---RTF     ZATNSVTSTY                 CPLSCFT      XAGFFXXEY                    TZXTVVXNY       ------AXSV
YXG---GAF    YATAGEMMAF                 FLZAMZSTY    XQ----ZY                     VZ---TTF        XHWPVNEX
-P---PSSGY   TARVXSVEY                  TVXDSZTHY    FQ---TX                      YN---ZXF        -H-----PVF
TP---GRMY    MPAADYEVAF                 AQAAPFAGY    TP---AZAF                    -M--SYZNF       XHEVZPXHX
PMFDZZVY     AAFCG---XV                 ----FGHY     VVATZNZZX                    SZFGCPTRF       -HGCPGMPX
AQEHGCAAZF   SPNEDXMZVF                 ALW--PZF                                  XGAXSN--EF      ETPEHAPVX
-M---GVHDY   VAATAGAVF                  VPHZNAY                                   RZAAYRXTY       MXPGNSAXYX
YVS--RNZY    XLH--ET                    -----GHGGY                                TNXHDGDGATZY
```

FIGURE 2. Pooled motifs obtained by Edman degradation and individual ligand data obtained by NanoES-MS/MS for the four B15 allotypes B*1508, B*1501, B*1503, and B*1510. Edman degradation was conducted as described with peptide extracts from each molecule; residues demonstrating a 2.0- to 3.5-fold picomolar increase over the previous degradation cycle are grouped as "strong," while those demonstrating an increase of >3.5-fold are grouped as "dominant." All of the individual ligands characterized from each allotype, whether classified as positive or negative for overlap status, are listed below the corresponding motifs. X denotes positional occupancy by the isomeric residues I or L, while Z denotes positional occupancy by the isobaric residues Q or K. Dashes (−) represent positions at which amino acids could not be unambiguously assigned through the NanoES-MS/MS fragmentation pattern and/or fractional Edman data obtained.

nonamers with both P2 and P9 anchors in concordance with their pooled Edman motifs.

Overlapping peptide ligands exhibit conserved C termini

Through the comparative mapping and sequencing approach outlined (Fig. 1), 19 peptide overlaps across B*1508 and B*1501 were defined. Similarly, seven ligands overlapping across B*1501 and B*1503 were identified, and four ligands were found to overlap across B*1508, B*1503, and B*1501. A conservative estimate is that our ion maps for each of the B15 allotypes represent 2000 individual peptides per molecule, yet B*1510 was not observed to share overlaps with the other three B15 allotypes in our ion maps (Fig. 4).

The data suggests that overlapping ligands bind across divergent B*1508, B*1501, and B*1503 binding grooves but are not permitted to do so by B*1510. This pattern emphasizes a dominant role for C-terminal anchors in natural peptide binding. Fig. 4 depicts, in the context of the class I peptide binding cleft, the locations of polymorphisms that individuate the four allotypes and highlights the anchoring residues for the peptide overlaps as indicated by their presenting molecule's respective motif (Fig. 2). Bolding the amino acids of these overlapping ligands, which are in agreement with the motifs, underscores the trend whereby a C-terminal anchor sequence is conserved in overlaps while the N-

proximal anchor is more flexible in its location and/or sequence. A lack of overlaps with B*1510 could be explained by the S→Y substitution at P116 (Table I). P116 participates in the C, E, and F Ag binding groove specificity pockets (41) and leaves valine (V) and leucine/isoleucine (X) as the preferred C-terminal anchors among most B*1510 ligands characterized (Fig. 2). Thus, the conserved C-terminal anchors that facilitate the occurrence of B*1508, B*1501, and B*1503 overlaps may fail to preferentially interact with the B*1510 C-terminal specificity pockets.

Length variation among overlapping ligands tends to mimic that observed among the total ligands characterized, previously discussed from Fig. 3. Notable exceptions were that overlaps between B*1501 and B*1503 were primarily octamers and that only one overlapping ligand was longer than 10 aa in length (Fig. 4). However, a limited number of B*1503 overlaps identified to date makes trends difficult to clearly establish regarding this B15 allotype.

Distilling the data from the 30 overlapping ligands so far identified leads us to suggest a model whereby the majority of ligands are first anchored into the binding groove by their C termini. In order for a peptide to stably remain in the groove, we propose that following rigid initial anchoring at the C terminus a ligand might be further tethered into the class I Ag binding cleft at a more elastic N-proximal position. Such could argue the case for peptide ligand NQZHGSAEY, a nonamer that overlaps across B*1508, B*1501,

(a)

(b)

FIGURE 3. Diversity among characterized HLA-B15 ligands. Graphed data from the B15 ligands listed in Fig. 1 summarizes both (*a*) length diversity and (*b*) sequence diversity at the P2 and C-terminal anchors, respectively, among the B*1508, B*1501, B*1503, and B*1510 peptides characterized.

and B*1503 (Fig. 1). According to this model (Fig. 5), a C-terminal tyrosine anchors NQZHGSAEY into all three B15 allotypes, while a glutamine at P2 anchors the peptide into B*1501 and B*1503 and a glutamine/lysine (Z; most likely a lysine based upon motif assignments and fractional Edman sequencing data) at P3 provides additional anchoring for B*1501 and serves as the sole N-proximal anchor for B*1508. Therefore, length and N-proximal specificity would appear to play more secondary roles in endogenous ligand binding of B15 peptide epitopes.

C-proximal auxiliary anchors are not apparent in B15 pooled motifs

Edman-derived motifs for the four B15 allotypes shown in Fig. 2 illustrate P2 and P9 dominant anchors and P3 auxiliary anchors, but these motifs fail to capture trends for auxiliary anchoring at the C-proximal regions of endogenously bound ligands. Specifically, additional anchor preferences occur at both P7 and P8 in the case of nonamers, octamers, and heptamers, while in the cases of ligands longer than nonamers the two residues internal to the C terminus, which we refer to as C^{-1} and C^{-2}, also act as auxiliary anchors. A glance through the individual B15 ligands shows that the amino acids threonine (T), serine (S), valine (V), and glutamine/lysine (Z) predominate at the C-proximal ends (involving either P7/P8 or C^{-1}/C^{-2}) of these ligands (Fig. 2). An example of how C-proximal auxiliary anchors impact endogenous ligand binding is that more than half of the peptides that overlap across the B*1508 and B*1501 Ag binding grooves bear threonine at P7 or P8, and in four cases the peptides that bind B*1508/1501 or B*1508/1501/1503 are heptamers with threonine occupying P7, their C-terminal positions (Fig. 4). The role of threonine as a C-proximal/C-terminal auxiliary anchor is best illustrated with the B*1508/1501/1503 overlapping heptamer CPLSCFT, where

threonine provides a C-terminal anchor not evident in the pooled motif.

Sources of individual B15 ligands reflect cytosolic Ag processing

Examples of peptides from this study with complete homology to stretches of known proteins are shown in Table II. The majority of ligands are derived from intracellular proteins, which illustrates the endogenous pathway is generating the class I-loaded peptides described here (2). Of the peptide sequences listed, six have also been reported by other laboratories. It is noteworthy that overlaps across other molecules of the HLA-B15 group are evident within this data collection: the B*1510 tapasin$_{354-362}$ ligand HHSDGS VSL has been sequenced from B*1509 extracts (36), and the B*1508/1501 ubiquitin-protein ligase$_{83-91}$-derived ligand ILGP PGSVY was characterized from endogenously bound B*1502 peptides (36). We identified the eIF3-p66$_{61-69}$ nonamer SQF GGGSQY (42, 43) within B*1508, B*1501, and B*1503 extracts. The decamer YMIDPSGVSY, which is homologous to proteasome subunit C8$_{150-159}$, was also previously described as a ligand for B*1502 (36), B*1508 (36), and B*4601 (42); we found it presented by B*1501 and by B*1508. Therefore, overlapping ligands identified here overlap in Ag presentation with the HLA-B15 allotypes characterized by others, and these overlaps are likewise determined by both flexible N-proximal anchor positions and conserved C-terminal anchor/C-proximal auxiliary anchor preferences.

Conclusions

The primary impetus for characterizing class I peptide ligands is to understand the functional impact of class I polymorphism in terms of endogenous ligand presentation. A fundamental realization of

B*1508 **B*1501** **B*1503** **B*1510**

```
--WDRHTXF          --WDRHTXF
-----YT            -----YT
TG----AY           TG----AY
FVSNHAY            FVSNHAY
SQFDHVTY           SQFDHVTY
XAN--VT            XAN--VT
FLZAMZSTY          FLZAMZSTY
TVXDSZTHY          TVXDSZTHY
VVACV---Y          VVACV---Y
PLA-N-HTY          PLA-N-HTY
VVAPITTGY          VVAPITTGY
FQARXTEY           FQARXTEY
VGYVDDTQF          VGYVDDTQF
TARVXSVEY          TARVXSVEY
AAFCG---XV         AAFCG---XV
YLH--ET            YLH--ET
ILGPPGSVY          ILGPPGSVY
XLGDVNMY           XLGDVNMY
YMIDPSGVSY         YMIDPSGVSY
```

```
NQZHGSAEY          NQZHGSAEY          NQZHGSAEY
TPXGEPYZSY         TPXGEPYZSY         TPXGEPYZSY
SQFGGGSQY          SQFGGGSQY          SQFGGGSQY
CPLSCFT            CPLSCFT            CPLSCFT
```

```
                   AQFASGAGZ          AQFASGAGZ
                   -G--CDY            -G--CDY
                   APMARGZY           APMARGZY
                   GQZZAVDF           GQZZAVDF
                   NPPAZZPN           NPPAZZPN
                   -Q-DPPPDMZY        -Q-DPPPDMZY
                   GQRKGAGSVF         GQRKGAGSVF
```

FIGURE 4. Overlapping HLA-B15 ligands identified by NanoES-MS mapping and characterized by NanoES-MS/MS. Ribbon diagrams of the class I Ag binding groove show residue substitutions (black, numbered) between B*1508, B*1503, and B*1510 with respect to the ancestral B15 allele B*1501 (*top*). Shown below the ribbons are three different groups of ligands identified that overlap the divergent binding grooves. The ligands are categorized from top to bottom as follows: peptides that overlap B*1508 and B*1501; peptides that overlap B*1508, B*1501, and B*1503; and peptides that overlap B*1501 and B*1503. No overlapping ligands have been identified to date between these three molecules and B*1510. Ligand residues that coincide with dominant and strong motif amino acids for the given motifs (Fig. 2) are indicated in bold type. X, Z, and dashes (−) are as defined in Fig. 2.

how naturally processed peptides bind both individual and multiple class I molecules can then be translated into peptide-based therapies to elicit protective CTL. Therefore, an accurate interpre-

B*1508 (N) (Q) (Z) (H) (G) (S) (A) (E) (Y)

1 2 3 4 5 6 7 8 9

B*1501 (N) (Q) (Z) (H) (G) (S) (A) (E) (Y)

B*1503 (N) (Q) (Z) (H) (G) (S) (A) (E) (Y)

FIGURE 5. N-proximal and C-terminal anchoring of the B*1508/1501/1503-overlapping nonamer NQZHGSAEY. The shared C-terminal anchoring preference for tyrosine in the NQZHGSAEY ligand among B*1508, B*1501, and B*1503 as defined by the respective motifs (Fig. 2) are shaded black, while the varied N-proximal anchoring preferences likewise reflected in the motifs are shaded gray. Residues are numbered sequentially from the N-terminus.

tation of peptide sequence data, either individual or pooled, will in turn further the selection of optimal viral and tumor-associated ligands for therapeutic applications.

Our examination of numerous B15 ligands enhances understanding the rules that govern class I peptide presentation. Building upon the pooled peptide motif, our data indicates that queries for potential epitopes specific to these allotypes might be optimized in three ways. First, although nonamers represent half the ligand population, peptide epitopes can range in length from 7 to 12 aa. Second, effective N-proximal anchors need not be positioned strictly at P2. Third, searches for ligands should most heavily weight C-terminal sequence matches.

In summary, divergent HLA-B15 molecules appear to present similar peptide ligands as long as polymorphisms do not alter C-terminal anchoring pockets and while an N-proximal ligand residue can be subsequently anchored within the Ag binding groove. Supporting data suggests that these principles might extend beyond the four B15 allotypes studied here. Specifically, unpublished results by Ghosh and Wiley (noted in Ref. 44) indicate that an octamer has been observed to successfully bind a class I molecule

Table II. *Summary of specific ligands characterized from the HLA-B15 allotypes*

Allele(s)	Ligand	Source Protein	References
B*1508, B*1501, B*1503	SQFGGGSQY	eIF3-p66 (61–69)[a]	42, 43, this study
B*1508, B*1501, B*1503	CPLSCFT	HTGS database[b]	This study
B*1501, B*1503	GQRKGAGSVF	Ribosomal protein L8 (7–16)	42, this study
B*1508, B*1501	FVSNHAY	Aldolase (358–364)	This study
B*1508, B*1501	VVAPITTGY	Calcyclin binding protein (63–71)	This study
B*1508, B*1501	VGYVDDTQF	HLA-I α (25–33)	This study
B*1502,[c] B*1508, B*1501	ILGPPGSVY	Ubiquitin-protein ligase (83–91)	36, this study
B*4601,[c] B*1502,[c] B*1508,[c] B*1501	YMIDPSGVSY	Proteasome subunit C8 (150–159)	42, 36, this study
B*1501	VQGPVGTDF	Zinc finger transcription factor (296–304)	This study
B*1503	IKADHVSTY	HLA-II DPα (32–40)	This study
B*1508	LPHQPLATY	Oct-binding factor 1 (52–60)	36, this study
B*1510	EHVASSPAL	13S Golgi transport complex 90 kDa subunit (741–749)	This study
B*1510	NHAIVSTSV	26S protease (S4) regulatory subunit (119–127)	This study
B*1509,[c] B*1510	HHSDGSVSL	Tapasin (354–362)	36, this study

[a] Residues are numbered from the initiating residue of the mature proteins.
[b] Peptide sequence demonstrated homology within the high-throughput genomic sequencing database.
[c] HLA-B15 allotype other than B*1508, B*1501, B*1503, or B*1510 from which the ligand was previously characterized.

by its C terminus despite being shown through x-ray crystallography to not even reach the N-terminal pocket of the binding groove. In addition, a recently described HIV-gag$_{197–205}$ CTL epitope presented by murine class I K^d fails to show a motif-prescribed tyrosine at P2 and instead associates stably through its conserved C terminus and an N-proximal preference for glutamine at P3 (23). It will be interesting to see through future studies whether endogenous ligands eluted from other HLA-B, as well as HLA-A and HLA-C, molecules confirm this speculation by exhibiting conserved C termini along with length and N-proximal sequence versatility.

Acknowledgments

References

1. Björkman, P. J., and P. Parham. 1990. Structure, function and diversity of class I major histocompatibility molecules. *Annu. Rev. Biochem. 59:253.*
2. York, I. A., and K. L. Rock. 1996. Antigen processing and presentation by the class I major histocompatibility complex. *Annu. Rev. Immunol. 14:369.*
3. Townsend, A., and H. Bodmer. 1989. Antigen recognition by class I restricted T lymphocytes. *Annu. Rev. Immunol. 7:601.*
4. Townsend, A. R. M., F. M. Gotch, and J. Davey. 1985. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. *Cell 42:457.*
5. Slingluff, C. L., A. L. Cox, R. A. Henderson, D. L. Hunt, and V. H. Engelhard. 1993. Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. *J. Immunol. 150:2955.*
6. Tsomides, T. J., A. Aldovini, R. P. Johnson, B. D. Walker, R. A. Young, and H. N. Eisen. 1994. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. *J. Exp. Med. 180:1283.*
7. Mazzocchi, A., W. J. Storkus, C. Traversari, P. Tarsini, M. J. Maeurer, L. Rivoltini, C. Vegetti, F. Belli, A. Anichini, G. Parmiani, and C. Castelli. 1996. Multiple myeloma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. *J. Immunol. 157:3030.*
8. Zinkernagel, R. M., and P. C. Doherty. 1974. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. *Nature 248:701.*
9. Heemels, M.-T., and H. Ploegh. 1995. Generation, translocation, and presentation of MHC class I-restricted peptides. *Annu. Rev. Biochem. 64:463.*
10. Harty, J. T., and M. J. Bevan. 1992. CD8$^+$ T cells specific for a single nonamer epitope of *Listeria monocytogenes* are protective in vivo. *J. Exp. Med. 175:1531.*
11. Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. L. Hunt, and C. L. Slingluff. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. *Science 264: 716.*
12. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. *J. Exp. Med. 180:347.*
13. Kulkarni, A. B., P. L. Collins, I. Bacik, J. W. Yewdell, J. R. Bennink, J. E. Crowe, Jr., and B. R. Murphy. 1995. Cytotoxic T-cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. *J. Virol. 69:1261.*
14. Vitiello, A., G. Ishioka, H. M. Grey, R. Rose, P. Farness, R. LaFond, L. Yuan, F. V. Chisari, J. Furze, R. Bartholomeuz, and R. W. Chesnut. 1995. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. *J. Clin. Invest. 95:341.*
15. Skipper, J. C. A., D. J. Kittlesen, R. C. Hendrickson, D. D. Deacon, N. L. Harthun, S. N. Wagner, D. F. Hunt, V. H. Engelhard, and C. L. Slingluff. 1996. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pme-17/gp100. *J. Immunol. 157:5027.*
16. Butterfield, L. H., S. M. Jilani, N. G. Chakraborty, L. A. Bui, A. Ribas, V. B. Dissette, R. Lau, S. C. Gamradt, J. A. Glaspy, W. H. McBride, B. Mukherji, and J. S. Economou. 1998. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. *J. Immunol. 161:5607.*
17. Falk, K., O. Rötzschke, S. Stevanovic, G. Jung, and H.-G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self peptides eluted from MHC molecules. *Nature 351:290.*
18. Pamer, E. G., J. T. Harty, and M. J. Bevan. 1991. Precise prediction of a dominant class I MHC-restricted epitope of *Listeria monocytogenes*. *Nature 353:852.*
19. Kast, W. M., R. M. P. Brandt, J. Sidney, J.-W. Drijfhout, R. T. Kubo, H. M. Grey, C. J. M. Melief, and A. Sette. 1994. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. *J. Immunol. 152:3904.*
20. Rammensee, H.-G., J. Bachmann, and S. Stevanovic, eds. *MHC Ligands and Peptide Motifs*. Landes Bioscience, Austin, Texas, pp. 236–281.
21. Prilliman, K. R., M. Lindsey, K. W. Jackson, J. Cole, R. Bonner, and W. H. Hildebrand. 1998. Complexity among constituents of the HLA-B*1501 peptide motif. *Immunogenetics 48:89.*
22. Malarkannan, S., F. Gonzalez, V. Nguyen, G. Adair, and N. Shastri. 1996. Alloreactive CD8$^+$ T cells can recognize unusual, rare, and unique processed peptide/MHC complexes. *J. Immunol. 157:4464.*
23. Mata, M., P. J. Travers, Q. Liu, F. R. Frankel, and Y. Paterson. 1998. The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to K^d through interactions between a glutamine at P3 and pocket D. *J. Immunol. 161: 2985.*
24. Prilliman, K., M. Lindsey, Y. Zuo, K. W. Jackson, Y. Zhang, and W. Hildebrand. 1997. Large-scale production of class I bound peptides: assigning a signature to HLA-B*1501. *Immunogenetics 45:379.*
25. Kavathas, P., F. H. Bach, and R. DeMars. 1980. Gamma ray-induced loss of expression of HLA and glyoxalase I alleles in lymphoblastoid cells. *Proc. Natl. Acad. Sci. USA 77:4251.*
26. Barnstable, C. J., W. F. Bodmer, G. Brown, G. Galfre, C. Milstein, A. F. Williams, and A. Ziegler. 1978. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens: new tools for genetic analysis. *Cell 14:9.*
27. Veronese, F. M., D. Arnott, V. Barnaba, D. J. Loftus, K. Sakaguchi, C. B. Thompson, S. Salemi, C. Mastroianni, A. Sette, J. Shabanowitz, D. F. Hunt, and E. Appella. 1996. Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects. *J. Exp. Med. 183:2509.*
28. Barber, L. D., B. Gillece-Castro, L. Percival, X. Li, C. Clayberger, and P. Parham. 1995. Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes. *Curr. Biol. 5:179.*

29. Whalen, K., S. Grossert, and R. K. Boyd. 1995. Ion dissociation reactions induced in a high-pressure quadrupole collision cell. *Rapid Commun. Mass Spectrom. 9:1366.*

30. Mann, M., and M. Wilm. 1994. Error-tolerant identification of peptides in sequence databases by peptide sequence tags. *Anal. Chem. 66:4390.*

31. Altschul, S. F., T. L. Madden, A. A. Schäffer, J. Zhang, Z. Zhang, W. Miller, and D. J. Lipman. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res. 25:3389.*

32. Sidney, J., M.-F. del Guercio, S. Southwood, V. H. Engelhard, E. Appella, H.-G. Rammensee, K. Falk, O. Rötzschke, M. Takiguchi, R. T. Kubo, H. M. Grey, and A. Sette. 1995. Several HLA alleles share overlapping peptide specificities. *J. Immunol. 154:247.*

33. del Guercio, M.-F., J. Sidney, G. Hermanson, C. Perez, H. M. Grey, R. T. Kubo, and A. Sette. 1995. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. *J. Immunol. 154:685.*

34. Kikuchi, A., T. Sakaguchi, K. Miwa, Y. Takamiya, H.-G. Rammensee, Y. Kaneko, and M. Takiguchi. 1996. Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket. *Immunogenetics 43:268.*

35. Sidney, J., H. M. Grey, S. Southwood, E. Celis, P. A. Wentworth, M.-F. del Guercio, R. T. Kubo, R. W. Chestnut, and A. Sette. 1996. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. *Hum. Immunol. 45:79.*

36. Barber, L. D., L. Percival, K. L. Arnett, J. E. Gumperz, L. Chen, and P. Parham. 1997. Polymorphism in the α1 helix of the HLA-B heavy chain can have an overriding influence on peptide-binding specificity. *J. Immunol. 158:1660.*

37. Fleischhauer, K., D. Avila, F. Vilbois, C. Traversari, C. Bordignon, and H.-J. Wallny. 1994. Characterization of natural peptide ligands for HLA-B*4402 and -B*4403: implications for peptide involvement in allorecognition of a single amino acid change in the HLA-B44 heavy chain. *Tissue Antigens 44:311.*

38. Paradela, A., M. García-Peydró, J. Vazquez, D. Rognan, and J. López de Castro. 1998. The same natural ligand is involved in allorecognition of multiple HLA-B27 subtypes by a single T cell clone: role of peptide and the MHC molecule in alloreactivity. *J. Immunol. 161:5481.*

39. Roepstorff, P., and J. Fohlman. 1984. Proposal for a common nomenclature for sequence ions in mass spectra of peptides. *Biomed. Mass Spectrom. 11:601.*

40. Hildebrand, W. H., J. D. Domena, S. Y. Shen, M. Bunce, S. G. E. Marsh, W. B. Bias, and P. Parham. 1994. HLA-B15: a widespread and diverse family of HLA-B alleles. *Tissue Antigens 43:209.*

41. Saper, M. A., P. J. Björkman, and D. C. Wiley. 1991. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution. *J. Mol. Biol. 219:277.*

42. Barber, L. D., L. Percival, N. M. Valiante, L. Chen, C. Lee, J. E. Gumperz, J. H. Phillips, L. L. Lanier, J. C. Bigge, R. B. Parekh, and P. Parham. 1996. The inter-locus recombinant HLA-B*4601 has high selectivity in peptide binding and functions characteristic of HLA-C. *J. Exp. Med. 184:735.*

43. Falk, F., O. Rötzschke, M. Takiguchi, V. Gnau, S. Stevanovic, G. Jung, and H.-G. Rammensee. 1995. Peptide motifs of HLA-B58, B60, B61, and B62 molecules. *Immunogenetics 41:165.*

44. Bouvier, M., and D. C. Wiley. 1994. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. *Science 265:398.*